![James Hudleston](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
James Hudleston currently works at iosBio Ltd., as Non-Executive Director.
Aktive Positionen von James Hudleston
Unternehmen | Position | Beginn |
---|---|---|
iosBio Ltd.
![]() iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
iosBio Ltd.
![]() iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | Technology Services |